The Patent Finder
BP

Biomunex Pharmaceuticals

First filing 2018
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Five patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2037. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2037
Next term end
4
Patent families

When these terms end

Each bar runs from grant to computed term end. 2022 to 2037.
US 12,528,877 Binding Molecules to CD38 and PD-L1 Mar 27, 2037
US 12,054,550 Bispecific Antibodies Targeting Egfr and HER2 Apr 28, 2037
US 11,958,913 A Polypeptide Linker for Preparing Multispecific Antibodies Apr 28, 2037
US 11,505,616 Binding Molecules to CD38 and PD-L1 Oct 31, 2037
US 11,560,437 Stable Multispecific Antibodies Oct 31, 2037
20252028203120342037
3 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Oct 16, 2027
    The maintenance fee for A Polypeptide Linker for Preparing Multispecific Antibodies (US 11,958,913) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 5 of 5

PatentTitleStatusExpiresConfidence
US 12,528,877Binding Molecules to CD38 and PD-L1
In force
 · High confidence
In forceHigh confidence
US 11,958,913A Polypeptide Linker for Preparing Multispecific Antibodies
In force
 · High confidence
In forceHigh confidence
US 12,054,550Bispecific Antibodies Targeting Egfr and HER2
In force
 · High confidence
In forceHigh confidence
US 11,505,616Binding Molecules to CD38 and PD-L1
In force
 · High confidence
In forceHigh confidence
US 11,560,437Stable Multispecific Antibodies
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 5: 3 applications pending. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited